Observed localization of the long-term cultured rat adherent natural killer cells in mammary tumor tissues.
Adherent natural killer (A-NK) cells were isolated from splenic lymphocytes and treated with long-term culture in the presence of recombinant interleukin-2 (rIL-2). Immunocytochemical and flow-cytometric analysis revealed that most of the A-NK cells strongly expressed lymphocyte-function-associated antigen 1 (LFA-1alpha, and LFA-1beta) throughout the incubation. All A-NK cells from 8- to 150-day cultures, particularly those cultured for 8 days, showed significant cytolytic activity against all targets. Analysis of the tissue distribution of the injected [3H] uridine-labeled A-NK cells demonstrated that, in the first 3 h, most (over 60%) cells localized in the lungs, and that most cells remained temporally within the cavities of blood capillaries of the lungs and moved gradually into lymphoid and other tissues. Peritumoral injection of various kinds of adjuvant, particularly Freund's complete adjuvant (FCA) plus bacillus Calmetee-Guerin (BCG), resulted in a marked accumulation of [3H]A-NK cells in mammary tumor tissues 24 h after injection, and simultaneously in the formation of vessels resembling high-endothelium venules (HEV), infiltration of LFA-1+ lymphocytes and expression of the ICAM-1 molecule on the tumor cells in the sites of tumor tissues. When 30 x 10(6) A-NK cells were intravenously administered, significant retardation of tumor growth and prolongation of survival of tumor-bearing rats were observed in the groups that received the prior injection of adjuvants, especially FCA + BCG and Freund's incomplete adjuvant (FIA) + BCG. The suppressive effect of combination therapy on tumor growth was blocked effectively by the injection of anti-ICAM-1 mAb. These results indicate that the prior injection of proper adjuvant into the peritumoral region is effective for the selective accumulation or infiltration of A-NK cells into the sites of tumor tissues, and results in the marked retardation of tumor growth.
Gu
S
S
Department of Anatomy, Hamamatsu University School of Medicine, Japan. shouzhi@hama-med.ac.jp
Furukawa
H
H
Yamashita
A
A
D000276:Adjuvants, Immunologic; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D001500:BCG Vaccine / Q000008:administration & dosage; D002196:Capillaries; D002478:Cells, Cultured / Q000637:transplantation; D003602:Cytotoxicity, Immunologic; D005260:Female; D005620:Freund's Adjuvant / Q000008:administration & dosage; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use; D016219:Immunotherapy, Adoptive; D015552:Injections, Intralesional; D007275:Injections, Intravenous; D018799:Intercellular Adhesion Molecule-1 / Q000032:analysis / Q000276:immunology; D007376:Interleukin-2 / Q000494:pharmacology / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000637:transplantation*; D008168:Lung / Q000098:blood supply / Q000276:immunology / Q000473:pathology; D016169:Lymphocyte Function-Associated Antigen-1 / Q000032:analysis; D008221:Lymphoid Tissue / Q000473:pathology; D008325:Mammary Neoplasms, Experimental / Q000276:immunology / Q000473:pathology* / Q000628:therapy; D009363:Neoplasm Proteins / Q000032:analysis / Q000276:immunology; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic; D051381:Rats; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D013047:Specific Pathogen-Free Organisms; D014018:Tissue Distribution
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D001500:BCG Vaccine; D007155:Immunologic Factors; D007376:Interleukin-2; D016169:Lymphocyte Function-Associated Antigen-1; D009363:Neoplasm Proteins; D011994:Recombinant Proteins; D018799:Intercellular Adhesion Molecule-1; D005620:Freund's Adjuvant